^
Association details:
Biomarker:No biomarker
Cancer:Clear Cell Renal Cell Carcinoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

Published date:
06/21/2022
Excerpt:
Nivolumab or cabozantinib should be offered to patients who progressed on a VEGFR TKI alone…
DOI:
10.1200/JCO.22.00868
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

Published date:
12/01/2021
Excerpt:
For second-line treatment, following TKIs, nivolumab [l, A; ESMO-MCBS v1.1 score: 5] or cabozantinib is recommended [l, A; ESMO-MCBS v1.1 score: 3]….In patients already treated with two lines of TKI therapy and whose disease has progressed, either nivolumab [I, A; ESMO-MCBS v1.1 score: 5] or cabozantinib [I, A; ESMO-MCBS v1.1 score: 3] may be considered.
DOI:
https://doi.org/10.1016/j.esmoop.2021.100304